Smith, M. A., Hampton, O. A., Reynolds, C. P., Kang, M. H., Maris, J. M., Gorlick, R., . . . Houghton, P. J. (2014). Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 by the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional in Vivo Response to BMN 673. Pediatr Blood Cancer.
Chicago-стиль цитированияSmith, Malcolm A., et al. "Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 By the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional in Vivo Response to BMN 673." Pediatr Blood Cancer 2014.
MLA-цитированиеSmith, Malcolm A., et al. "Initial Testing (Stage 1) of the PARP Inhibitor BMN 673 By the Pediatric Preclinical Testing Program: PALB2 Mutation Predicts Exceptional in Vivo Response to BMN 673." Pediatr Blood Cancer 2014.